Cassava Sciences stock holds near recent lows as biotech losses and mixed sentiment weigh

Cassava Sciences stock (ISIN US14428V1035) remains under pressure, with recent data pointing to a weak performance over the past year and a price close to its 52-week low as of September 18, 2026. For investors, the story is currently driven by losses and mixed analyst sentiment rather than a single fresh company catalyst.

Biotech losses dominate the current picture

According to Pluang, Cassava Sciences reported a net loss of USD 90.97 million for fiscal year 2025, underscoring the company’s challenge in funding Alzheimer’s research without profitable products on the market. The same overview notes that, despite this loss, the company beat earnings-per-share estimates for three consecutive quarters through 2025 and early 2026, a pattern that highlights how expectations had been set very low for the biotech.

In the broader performance context, a German-language stock portal reports that Cassava Sciences shares show a one-year performance of around minus 63.73 percent, with a 52-week performance of about minus 67.32 percent, placing the stock far behind typical health-care and biotechnology benchmarks.wallstreet-online These figures are historical context rather than current quarter data but show that the drawdown from earlier peaks has been severe.

Recent price levels and proximity to the 52-week low

Pluang’s latest snapshot lists Cassava Sciences, under the trading symbol FLNA on its platform, at USD 0.726 per share, up 6.11 percent in the last recorded session, with a 52-week low of USD 0.68 on September 16, 2026 and a 52-week high of USD 4.64.Pluang That places the recent price roughly 6.8 percent above the 52-week low and approximately 84.4 percent below the 52-week high, illustrating how much value has been erased over the past year.

The same German portal, which quotes a euro-denominated secondary price for Cassava Sciences shares, emphasizes the weak technical picture with the stock trading about 85.21 percent under its 52-week high and just 4.02 percent above its 52-week low as of mid-September 2026.wallstreet-online Even though the euro quote reflects trading on a different venue than Nasdaq in the United States, the relative positioning within the 52-week range mirrors the weak levels visible in the USD data.

Analyst sentiment and risk backdrop

Pluang describes analyst sentiment on Cassava Sciences as broadly positive, with 8 buy ratings versus 4 holds in its latest compiled view, but at the same time flags strong selling pressure in technical indicators and negative cash flows and earnings.Pluang The tension between supportive analyst ratings and weak fundamental performance is central for investors: it suggests that many recommendations are based on long-term trial outcomes rather than current profitability.

Meanwhile, the German portal summarizing Cassava Sciences notes that all analysts in its narrower sample rate the stock as Hold, and calculates a composite score of 3.00 out of 5 points.wallstreet-online For investors, this mix of Hold ratings and separate data showing several Buy recommendations in other overviews means that conviction is far from unanimous.

Stock remains tied to upcoming catalysts

With losses still large and the share price trading close to its 52-week low as of mid-September 2026, Cassava Sciences stock is highly sensitive to any future trial updates or regulatory developments. Neither Pluang nor the German portal currently lists a specific upcoming earnings date beyond routine calendar entries, but both emphasize that the company’s ability to improve cash flows and reduce its net loss will be critical in the next reporting cycles.Pluangwallstreet-online For now, the share price level relative to the 52-week low is the clearest numerical signal of the market’s caution.

Recent trading level on Nasdaq

Based on the latest available USD quote, Cassava Sciences stock can be approximated near USD 0.73 per share on its primary listing on Nasdaq, as of a recent completed trading session in mid-September 2026, with the price standing less than 10 percent above the 52-week low and more than 80 percent below the 52-week high, in line with data from Pluang and other portals.Pluang This keeps Cassava Sciences firmly in the high-risk biotech category, where any positive clinical or regulatory news could trigger sharp moves, but where recent history has been dominated by losses and downward pressure on the stock.

More news and analyses on Cassava Sciences stock